Details for Patent: 7,396,841
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which drugs does patent 7,396,841 protect, and when does it expire?
Patent 7,396,841 protects PREVACID IV and is included in one NDA.
Protection for PREVACID IV has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has six patent family members in five countries.
This patent has expired prematurely due to non-payment of maintenance fees. See details below.
Summary for Patent: 7,396,841
Title: | Injections |
Abstract: | An injectable composition comprises a benzimidazole compound having an antiulcer action and a strong alkali (e.g., an alkali metal hydroxide such as sodium hydroxide) in a proportion of about 1 equivalent of the latter relative to 1 mol of the former, and is substantially free from a nonaqueous solvent. The injectable composition may comprise N-methylglucamine, and a saccharide (such as mannitol). The injectable composition may be a freeze-dried preparation. The freeze-dried preparation is dissolvable in or dilutive with a distilled water for injection or an infusion solution without a nonaqueous solvent. The injectable composition is useful as an antiulcer agent. |
Inventor(s): | Doen; Takayuki (Suita, JP), Nagao; Masao (Kashiba, JP), Asakawa; Naoki (Takatsuki, JP), Takechi; Nobuyuki (Osaka, JP) |
Assignee: | Takeda Pharmaceutical Company Limited (Osaka, JP) |
Application Number: | 10/344,805 |
Patent Claim Types: see list of patent claims | Composition; Compound; Formulation; Process; Use; |
Drugs Protected by US Patent 7,396,841
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Takeda Pharms Na | PREVACID IV | lansoprazole | INJECTABLE;INTRAVENOUS | 021566-001 | May 27, 2004 | DISCN | Yes | No | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 7,396,841
Foriegn Application Priority Data | ||
Foreign Country | Foreign Patent Number | Foreign Patent Date |
Japan | 2000-248468 | Aug 18, 2000 |
PCT Information | |||
PCT Filed | August 17, 2001 | PCT Application Number: | PCT/JP01/07075 |
PCT Publication Date: | February 28, 2002 | PCT Publication Number: | WO02/15908 |
International Family Members for US Patent 7,396,841
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Australia | 7875501 | See Plans and Pricing | |||
Canada | 2419067 | See Plans and Pricing | |||
European Patent Office | 1310252 | See Plans and Pricing | |||
Japan | 2002128675 | See Plans and Pricing | |||
Japan | 4136340 | See Plans and Pricing | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |